The complaint, filed by the Law Offices of Frank R. Cruz, alleges that Capricor executives issued misleading statements between December 17, 2025, and July 26, 2026. According to the filing, the company modified its statistical analysis plan for Deramiocel clinical data without prior FDA consensus. This lack of alignment allegedly created a significant risk that the agency would reject the drug’s effectiveness, jeopardizing the Biologics License Application (BLA) process.
The lawsuit contends that these omissions rendered the company's public assurances regarding its operational prospects materially false. Investors affected by the stock's performance during this period may contact the firm at 310-914-5007 or via email to evaluate their legal standing. Participation as a lead plaintiff is optional; those who choose not to act remain absent class members by default.
Comments (0)
No comments yet. Be the first!